Unlock stock picks and a broker-level newsfeed that powers Wall Street.
July 2024 Insights Into Three SEHK Stocks Estimated To Be Undervalued

In This Article:

Amidst a backdrop of fluctuating global markets, the Hong Kong stock market has shown signs of potential undervaluation in several sectors. This presents an intriguing opportunity for investors to consider stocks that may be poised for recovery or growth as market dynamics evolve. In identifying undervalued stocks, it's crucial to look for companies with strong fundamentals, including robust earnings potential and stable financial health, which may be overlooked in turbulent times.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name

Current Price

Fair Value (Est)

Discount (Est)

Giant Biogene Holding (SEHK:2367)

HK$39.60

HK$75.71

47.7%

Beauty Farm Medical and Health Industry (SEHK:2373)

HK$16.84

HK$33.00

49%

China Cinda Asset Management (SEHK:1359)

HK$0.66

HK$1.29

48.8%

West China Cement (SEHK:2233)

HK$1.08

HK$2.15

49.7%

Mobvista (SEHK:1860)

HK$1.84

HK$3.67

49.8%

BYD (SEHK:1211)

HK$233.00

HK$460.29

49.4%

Hangzhou SF Intra-city Industrial (SEHK:9699)

HK$10.30

HK$19.58

47.4%

AK Medical Holdings (SEHK:1789)

HK$4.48

HK$7.96

43.7%

Vobile Group (SEHK:3738)

HK$1.19

HK$2.30

48.3%

MicroPort Scientific (SEHK:853)

HK$5.07

HK$9.41

46.1%

Click here to see the full list of 42 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Pacific Textiles Holdings

Overview: Pacific Textiles Holdings Limited is engaged in the manufacturing and trading of textile products across a diverse set of regions including China, Vietnam, Bangladesh, Hong Kong, and internationally, with a market capitalization of approximately HK$2.43 billion.

Operations: The company generates HK$4.67 billion from its manufacturing and trading of textile products.

Estimated Discount To Fair Value: 37.1%

Pacific Textiles Holdings, trading at HK$1.74, appears undervalued based on a DCF valuation that suggests a fair value of HK$2.77. Despite recent earnings declines—net income fell to HK$167.12 million from HK$268.57 million—the company's future looks promising with expected earnings growth of 37.67% per year, outpacing the Hong Kong market forecast of 11.4%. However, its dividend sustainability is questionable as it is poorly covered by both earnings and free cash flows.

SEHK:1382 Discounted Cash Flow as at Jul 2024
SEHK:1382 Discounted Cash Flow as at Jul 2024

Shanghai INT Medical Instruments

Overview: Shanghai INT Medical Instruments Co., Ltd. operates in the medical equipment industry and has a market capitalization of approximately HK$4.84 billion.